Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

  • Quanterix Corporation Releases Operating Results for Third Quarter 2019
    on November 6, 2019 at 9:01 pm

    Strong revenue growth and successful early launch of new HD-X Analyzer

  • Siemens Healthineers Enters into License and Supply Arrangement with Quanterix for Access to Neurofilament Light (Nf-L) Antibodies to Develop Nf-L Assays
    on November 4, 2019 at 9:00 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will allow Siemens Healthineers to begin developing blood-based Nf-L clinical tests for future commercialization. The agreement entered into with Siemens Healthineers marks yet another significant milestone in Quanterix’ mission to provide early detection of disease, measurements for treatment efficacy, and disease progression for neurological disorders.

  • Hedge Funds Have Never Been More Bullish On Quanterix Corporation (QTRX)
    on November 1, 2019 at 1:41 pm

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always

  • Quanterix Simoa Technology Unlocks Low-Level Markers Critical to Rapid Triage Test in Study for Active Pulmonary Tuberculosis
    on October 25, 2019 at 1:13 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa technology was used, in a recent study, as a rapid test for the triage of adult patients with persistent cough suspected to have active pulmonary tuberculosis (TB). “There are vast applications for our technology in hospitals, research organizations, academic institutions and field operations. This study shows the ultra-sensitive Simoa technology has the potential to provide the opportunity to identify and triage cohorts of patients at any stage of the disease,” said Kevin Hrusovsky, Chairman, President and CEO of Quanterix.

  • Quanterix to Release Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019
    on October 22, 2019 at 8:30 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for third quarter 2019 after the close of trading on Wednesday, November 6, 2019. Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix.

  • 3 Medical Product Stocks Likely to Beat This Earnings Season
    on October 18, 2019 at 3:13 pm

    Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

  • Quanterix Announces Recipients of Annual Accelerator Grant Program
    on October 3, 2019 at 1:00 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Shelli Kesler, Ph.D., and Ashley Henneghan, Ph.D., MSN, from the School of Nursing at the University of Texas at Austin, as the winners of its annual Accelerator Grant Program for their research proposal, “Neurodegenerative and Inflammatory Predictors of Cancer Related Cognitive Impairment in Breast Cancer Patients.” As recipients of the grant, Quanterix will award $50,000 toward the cost of their research in the company’s Accelerator Lab using Quanterix’ ultrasensitive Simoa technology.

  • Need To Know: Quanterix Corporation (NASDAQ:QTRX) Insiders Have Been Selling Shares
    on October 1, 2019 at 1:46 pm

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Quanterix Corporation (QTRX) Q2 2019 Earnings Call Transcript
    on August 7, 2019 at 12:25 pm

    QTRX earnings call for the period ending June 30, 2019.

This message is only visible to admins.

Problem displaying Facebook posts.
Click to show error

Error: (#10) To use "Page Public Content Access", your use of this endpoint must be reviewed and approved by Facebook.
Solution: See here for how to solve this error

We're committed to understanding brain health & the impact it has on our #veterans. Through our collaborations, we believe we're closer to understanding #TBI #CTE #PTSD in our veteran community. Those who live in freedom will always be grateful to those who helped preserve it.

Our team is excited to demonstrate our #acceleratorlab services at @AAPSComms’ #pharmsci360. Visit booth 1414 to learn more about the power of #simoa!

We are pleased to share that we’ve entered into an arrangement with @SiemensHealth to develop Nf-L assays that could change #patientcare for people living with neurodegenerative diseases like #Alzheimers, #MS, #ALS and more. Learn more: https://bit.ly/2Nh5N4j

Last week, our CEO @KevinHrusovsky spoke w/ Dr. Azra Raza of @ColumbiaMed to discuss the future of #oncology & how together we’re using #biomarker technology to stop the treatment cycle of “slash, poison & burn.” Head to @Medium for more: https://bit.ly/341pAtL

If you missed our live broadcast w/ Dr. Azra Raza of @ColumbiaMed last week, fear not. Our CEO, @KevinHrusovsky, reflects on their discussion & how Quanterix is partnering w/ her to incite change in the future of #oncology. Read the blog: https://bit.ly/2MLXYmH

.@GenomeWeb highlighted new research published this week in @ScienceTM using our Simoa technology as a rapid blood test for #tuberculosis. More on our role in this critical advance via @abonsilaw: https://bit.ly/2NpyiM3 #infectiousdiseases

Researchers David Leppert and Jens Kuhle explore how our Simoa #technology is making the use of NfL serum in clinical practice routine when it comes to monitoring #MS evolution: https://bit.ly/2JgP3rl @SAGE_News

Thank you to Dr. Raza of @ColumbiaMed for a great discussion on #cancer prevention and shifting the #healthcare paradigm in #oncology with #biomarker detection solutions like Simoa. More on Dr. Raza’s new book via @BasicBooks: https://bit.ly/35R7f4H

Load More...


What's Your Role?*



Company Description*



Quanterix Corporation

Building 1
900 Middlesex Turnpike
Billerica, MA 01821

+1 (617) 301-9400


November 2019
« Oct    

©2019 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account